Immunotherapy drug for treating HPV+ head and neck cancers hailed as "game-changer"
A new generation of “game-changing” drugs that harness the body’s immune system have been found to extend the lives of head and neck cancer sufferers. Ā The drug, Nivolumab, resulted in the doubling of one-year survival rates in clinical trials on HPV+ head and neck cancer patients. Ā Findings will be presented to the European Society for Medical Oncology Conference taking place in Copenhagen this week. Ā Nivolumab works by removing the switch so that immune cells can spot cancer cells and clear them out of the body. Ā Oracle’s Honorary Trustee, Professor Kevin Harrington, led this exciting trial.
Read the full article here https://www.bbc.co.uk/news/health-37588541
#TeamOracle completes Chiltern Challenge
Group of Oracle Cancer Trust Fundraisers complete 20 mile Chiltern Challenge on East Monday. The day started with dark skies and torrential rain, but that wasn’t going to stop our…
Katrinaā€™s Quiz nights
Katrina is one of our longest fundraisers and has held many quiz nights in support of Oracle over the years in her local village.
Follow us
Oracle Head & Neck Cancer UK is a registered charity in England and Wales (1142037), and in Scotland (SC052790).
Registered as a company limited by guarantee in England and Wales (7125497). Registered address: 80 Coombe Road, New Malden KT3 4QS.